Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellebrite DI (CLBT) Share-based Compensation (2020 - 2023)

Historic Share-based Compensation for Cellebrite DI (CLBT) over the last 5 years, with Q3 2025 value amounting to $15.3 million.

  • Cellebrite DI's Share-based Compensation rose 6905.58% to $15.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.2 million, marking a year-over-year increase of 5241.98%. This contributed to the annual value of $30.6 million for FY2024, which is 6093.8% up from last year.
  • Latest data reveals that Cellebrite DI reported Share-based Compensation of $15.3 million as of Q3 2025, which was up 6905.58% from $9.3 million recorded in Q4 2024.
  • Cellebrite DI's Share-based Compensation's 5-year high stood at $15.3 million during Q3 2025, with a 5-year trough of $1.4 million in Q3 2021.
  • In the last 5 years, Cellebrite DI's Share-based Compensation had a median value of $4.5 million in 2023 and averaged $5.2 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first skyrocketed by 14403.67% in 2022, then soared by 2760.06% in 2023.
  • Quarter analysis of 5 years shows Cellebrite DI's Share-based Compensation stood at $1.7 million in 2021, then surged by 128.0% to $3.8 million in 2022, then skyrocketed by 33.61% to $5.1 million in 2023, then surged by 83.18% to $9.3 million in 2024, then soared by 65.15% to $15.3 million in 2025.
  • Its Share-based Compensation was $15.3 million in Q3 2025, compared to $9.3 million in Q4 2024 and $9.1 million in Q3 2024.